U.S. Menopause Hormone Therapy Dispensing More Than Doubles 2023-2026
Monthly dispensing of menopause hormone therapy for U.S. women aged 40 to 74 more than doubled between 2023 and 2026, climbing from 2 million to 4.9 million fills, Science News reported on Thursday.
The estimated population dispensing rate jumped from 28 per 1,000 women to 67 per 1,000 women aged 40 to 74. Growth concentrated in transdermal and vaginal estrogen and progesterone products while oral pill use held flat.
The cross-sectional analysis, published on November 19, 2026, in JAMA, utilized national pharmacy dispensing data to evaluate treatment trends. Researchers Dana O. Sarnak, Wen Shen, and G. Caleb Alexander of Johns Hopkins University tracked utilization patterns across age groups, formulations, and delivery routes.
Using population data, the study estimated that the dispensing rate for women aged 40 to 74 jumped from 28 prescriptions per 1,000 women to 67 prescriptions per 1,000 women over the studied period, Science News reported.
The analysis revealed that growth in utilization began in 2024 and continued through 2025 and 2026, according to Science News. That upward trajectory preceded and followed a November 2025 regulatory action by the Food and Drug Administration.
The agency requested that manufacturers modify product labeling to remove boxed warnings regarding probable risks of breast cancer, cardiovascular disease, and probable dementia for patients receiving menopausal hormone therapy, as noted in a September 3, 2026, update from the U.S. Food and Drug Administration regarding estradiol transdermal patch availability. The FDA attributed a subsequent shortage of estrogen patches to this rising national demand.

Formulation trends shifted away from traditional oral pills toward newer delivery methods. The JAMA analysis showed that product use increased for transdermal patches, vaginal estrogen, and progesterone products, while the use of oral formulations remained stable, Science News reported.
Medical guidelines from organizations such as the Menopause Society recommend hormone therapy for symptomatic women younger than 60 or within 10 years of menopause onset, provided they lack risk factors such as prior breast cancer or stroke.
“Greater attention to women’s health, updated medical guidance supporting individualized menopause hormone therapy and social media may all be contributing to increased interest,” Dana Sarnak told Science News. Sarnak said that clinical colleagues report an increase in patients seeking menopause care.
Historical hesitation among patients and clinicians stems from the early 2000s Women’s Health Initiative study, which linked hormone pills to safety concerns that subsequent research found to be overblown. Current clinical approaches emphasize safer transdermal formulations, such as patches and gels, and mandate progesterone co-administration for women with an intact uterus.
The study was not designed to determine the precise drivers behind the increased dispensing rates, leaving open the exact weight of social media influence, updated clinical guidelines, and changing patient perceptions.
Johns Hopkins University, founded in 1876 in Baltimore as the nation’s first research university, pioneered the integration of teaching and scientific discovery that became the model for American higher education. Its School of Medicine, established in 1893, and the Bloomberg School of Public Health have driven landmark biomedical and population-health research for more than a century.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.